Minerva Biotechnologies Announces Opening 1^st-In-Human Phase I/II Trial of a MUC1* Targeting CAR T for Metastatic Breast Cancers at City of Hope

Minerva Biotechnologies Corporation announced that its trial of huMNC2-CAR44 T cells has now opened at City of Hope, Duarte, California. This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1*, the transmembrane cleavage product that is a growth factor receptor that drives growth of an estimated 93% of breast cancers.